Medicenna Therapeutics (TSE:MDNA) Stock Price Down 2.1% - Here's Why

Key Points

• Medicenna Therapeutics Corp.'s stock price fell 2.1%, trading at C$0.92 with a volume increase of 24% from the average daily volume.
• The company has a market cap of C$76.74 million and a debt-to-equity ratio of 0.88.
• Medicenna is focused on developing immuno-oncology treatments, particularly targeting the Interleukin-4 Receptor, which is linked to various cancers.

Medicenna Therapeutics Corp. (TSE:MDNA - ) dropped 2.1% during mid-day trading on Tuesday . The stock traded as low as C$0.92 and last traded at C$0.92. Approximately 53,666 shares changed hands during trading, an increase of 24% from the average daily volume of 43,145 shares. The stock had previously closed at C$0.94.

Medicenna Therapeutics Trading Down 2.1%

The company has a debt-to-equity ratio of 0.88, a quick ratio of 4.65 and a current ratio of 11.40. The company has a 50 day simple moving average of C$1.03 and a two-hundred day simple moving average of C$0.98. The company has a market cap of C$76.74 million, a PE ratio of -5.75 and a beta of 2.66.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.